| Literature DB >> 28052255 |
Alba Cristobal1, Henk W P van den Toorn1, Marc van de Wetering2, Hans Clevers3, Albert J R Heck4, Shabaz Mohammed5.
Abstract
Diseases at the molecular level are complex and patient dependent, necessitating development of strategies that enable precision treatment to optimize clinical outcomes. Organoid technology has recently been shown to have the potential to recapitulate the in vivo characteristics of the original individual's tissue in a three-dimensional in vitro culture system. Here, we present a quantitative mass-spectrometry-based proteomic analysis and a comparative transcriptomic analysis of human colorectal tumor and healthy organoids derived, in parallel, from seven patients. Although gene and protein signatures can be derived to distinguish the tumor organoid population from healthy organoids, our data clearly reveal that each patient possesses a distinct organoid signature at the proteomic level. We demonstrate that a personalized patient-specific organoid proteome profile can be related to the diagnosis of a patient and with future development contribute to the generation of personalized therapies.Entities:
Keywords: colorectal cancer; mass spectrometry; organoids; proteomics
Mesh:
Substances:
Year: 2017 PMID: 28052255 DOI: 10.1016/j.celrep.2016.12.016
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423